Engineered digoxigenin-binding protein (Anti-DIG)

Engineered digoxigenin-binding proteins, including humanized anti-digoxigenin (anti-DIG) antibodies and single-chain variable fragments (scFvs), serve as a versatile platform for targeted therapy and diagnostic applications (PMC 3107318). These proteins are designed to bind with high affinity to digoxigenin (DIG), a plant-derived steroid from the Digitalis genus that is not naturally present in the human body, making it an ideal orthogonal hapten for medical use (ResearchGate). In the context of bispecific antibodies, one arm targets a specific disease marker (such as HER2 or CD19) while the anti-DIG arm captures DIG-labeled payloads, including cytotoxic drugs, imaging agents, or therapeutic peptides, to ensure precise delivery to the site of disease (WO2012093068A1). Furthermore, these proteins are utilized in switchable chimeric antigen receptor (CAR) T-cell therapies, where the CAR-T cell expresses an anti-DIG receptor that only becomes active upon the administration of a DIG-labeled targeting adapter (PMC 4842728). This modular approach allows for the fine-tuning of immune responses and the ability to target multiple antigens with a single cell product. Additionally, engineered anti-DIG fragments are employed clinically to neutralize digoxin in cases of life-threatening toxicity by sequestering the drug in the intravascular space (Creative Biolabs).

Other names

Anti-digoxigenin antibodyAnti-DIG scFvDigoxigenin-binding moduleDig-binding proteinAnti-DIG Fab<Dig> antibody

Engineered digoxigenin-binding proteins act as molecular adapters or bridges in therapeutic systems. In bispecific antibody formats, one arm binds a disease-specific antigen while the anti-DIG arm captures a digoxigenin-labeled payload, facilitating targeted delivery of drugs or imaging agents (PMC 3107318). In switchable CAR-T cell therapies, the anti-DIG scFv serves as a synthetic receptor on the T-cell surface that only triggers activation when a DIG-labeled targeting 'switch' molecule bridges the T-cell to the tumor cell (PMC 4842728). Additionally, these proteins can neutralize digoxin in the bloodstream to treat life-threatening toxicity (StatPearls).